![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Harrison C. Bergeron & Ralph A. Tripp. (2022) Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert Opinion on Investigational Drugs 31:1, pages 23-29.
Read now
Read now
Sophie K. Wong, Abby Li, Krista L. Lanctôt & Bosco Paes. (2018) Adherence and outcomes: a systematic review of palivizumab utilization. Expert Review of Respiratory Medicine 12:1, pages 27-42.
Read now
Read now
Margarita K. Lay, Susan M. Bueno, Nicolás Gálvez, Claudia A. Riedel & Alexis M. Kalergis. (2016) New insights on the viral and host factors contributing to the airway pathogenesis caused by the respiratory syncytial virus. Critical Reviews in Microbiology 42:5, pages 800-812.
Read now
Read now
Haben Y Abraha, Krista L Lanctôt & Bosco Paes. (2015) Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Review of Respiratory Medicine 9:6, pages 779-799.
Read now
Read now
Articles from other publishers (16)
Xiao Yu, Anke J. Lakerveld, Sandra Imholz, Marion Hendriks, Sofie C. A. ten Brink, H. Lie Mulder, Karen de Haan, Rutger M. Schepp, Willem Luytjes, Menno D. de Jong, Josine van Beek & Puck B. van Kasteren. (2020) Antibody and Local Cytokine Response to Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults. mSphere 5:5.
Crossref
Crossref
Stephen MacAmanda SumnerSamuel Duchesne-BelangerRobert StirlingMatthew TunisBeate Sander. (2019) Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143:5.
Crossref
Crossref
Caroline Amand, Sabine Tong, Alexia Kieffer & Moe H. Kyaw. (2018) Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Services Research 18:1.
Crossref
Crossref
Shing-Yan Robert Lee, Ka Li Kwok, Daniel Kwok Keung Ng & Kam Lun Hon. (2018) Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection—A Cost-Effectiveness Analysis. Journal of Tropical Pediatrics 64:5, pages 418-425.
Crossref
Crossref
Ansul Asad. (2018) Common Queries About Immunizations in Preterm Infants. Pediatric Annals 47:4.
Crossref
Crossref
Natalia Olchanski, Ryan N Hansen, Elle Pope, Brittany D’Cruz, Jaime Fergie, Mitchell Goldstein, Leonard R Krilov, Kimmie K McLaurin, Barbara Nabrit-Stephens, Gerald Oster, Kenneth Schaecher, Fadia T Shaya, Peter J Neumann & Sean D Sullivan. (2018) Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infectious Diseases 5:3.
Crossref
Crossref
Megan E. Schmidt, Cory J. Knudson, Stacey M. Hartwig, Lecia L. Pewe, David K. Meyerholz, Ryan A. Langlois, John T. Harty & Steven M. Varga. (2018) Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. PLOS Pathogens 14:1, pages e1006810.
Crossref
Crossref
A. Banerji, K. Ng, T. J. Moraes, V. Panzov, J. Robinson & B. E. Lee. (2016) Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic. CMAJ Open 4:4, pages E623-E633.
Crossref
Crossref
Seth A. Schobel, Karla M. Stucker, Martin L. Moore, Larry J. Anderson, Emma K. Larkin, Jyoti Shankar, Jayati Bera, Vinita Puri, Meghan H. Shilts, Christian Rosas-Salazar, Rebecca A. Halpin, Nadia Fedorova, Susmita Shrivastava, Timothy B. Stockwell, R. Stokes Peebles, Tina V. Hartert & Suman R. Das. (2016) Respiratory Syncytial Virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Scientific Reports 6:1.
Crossref
Crossref
B. Bailly, C.-A. Richard, G. Sharma, L. Wang, L. Johansen, J. Cao, V. Pendharkar, D.-C. Sharma, M. Galloux, Y. Wang, R. Cui, G. Zou, P. Guillon, M. von Itzstein, J.-F. Eléouët & R. Altmeyer. (2016) Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication. Scientific Reports 6:1.
Crossref
Crossref
Parco Chan, Abby Li, Bosco Paes, Haben Abraha, Ian Mitchell & Krista L. Lanctôt. (2015) Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Pediatric Infectious Disease Journal 34:12, pages e290-e297.
Crossref
Crossref
Robert Tinnion, Jill Spencer, Samantha Moss & Alan Fenton. (2015) RSV: Immunoprophylaxis and non-invasive respiratory support in ex-preterms: A northern UK perspective. Pediatric Pulmonology 50:11, pages 1119-1127.
Crossref
Crossref
Paul M. Brown, Dana L. Schneeberger & Giovanni Piedimonte. (2015) Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity. Paediatric Respiratory Reviews 16:4, pages 232-240.
Crossref
Crossref
Daniel M. Weinberger, Joshua L. Warren, Claudia A. Steiner, Vivek Charu, Cécile Viboud & Virginia E. Pitzer. (2015) Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus. Clinical Infectious Diseases 61:4, pages 506-514.
Crossref
Crossref
Gang Luo, Flory L. Nkoy, Per H. Gesteland, Tiffany S. Glasgow & Bryan L. Stone. (2014) A systematic review of predictive modeling for bronchiolitis. International Journal of Medical Informatics 83:10, pages 691-714.
Crossref
Crossref
Andrew HiattNatasha BohorovaOgnian BohorovCharles GoodmanDo KimMichael H. PaulyJesus VelascoKevin J. WhaleyPedro A. Piedra, Brian E. Gilbert & Larry Zeitlin. (2014) Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proceedings of the National Academy of Sciences 111:16, pages 5992-5997.
Crossref
Crossref